世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
Clinical Oncology Next Generation Sequencing Market Summary The global clinical oncology next generation sequencing market size was estimated at USD 482.3 million in 2024 and is projected to rea... もっと見る
SummaryClinical Oncology Next Generation Sequencing Market SummaryThe global clinical oncology next generation sequencing market size was estimated at USD 482.3 million in 2024 and is projected to reach USD 1,930.2 million by 2033, growing at a CAGR of 16.77% from 2025 to 2033. The key drivers responsible for the growth of the clinical oncology next generation sequencing (NGS) industry are increasing technological advancements, growing competition among players, increasing healthcare spending, and the rise in the prevalence of cancer. In addition, augmenting research & development activities to invent solutions is expected to fuel the market growth over the forecast period. Global Clinical Oncology Next Generation Sequencing Market Report Segmentation This report forecasts revenue growth at the global, regional, and country levels and analyzes the latest industry trends in each sub-segment from 2021 to 2033. Grand View Research has segmented the global clinical oncology next generation sequencing market report based on workflow, technology, application, end use, and region. • Workflow Outlook (Revenue, USD Million, 2021 - 2033) • NGS Pre-Sequencing • NGS Sequencing • NGS Data Analysis • Technology Outlook (Revenue, USD Million, 2021 - 2033) • Whole Genome Sequencing • Whole Exome Sequencing • Targeted Sequencing & Resequencing • Application Outlook (Revenue, USD Million, 2021 - 2033) • Screening o Sporadic Cancer o Inherited Cancer • Companion Diagnostics • Others • End Use Outlook (Revenue, USD Million, 2021 - 2033) • Hospitals • Clinics • Laboratories • Regional Outlook (Revenue, USD Million, 2021 - 2033) • North America o U.S. o Canada o Mexico • Europe o UK o Germany o France o Italy o Spain o Denmark o Sweden o Norway • Asia Pacific o Japan o China o India o Australia o South Korea o Thailand • Latin America o Brazil o Argentina • Middle East & Africa o South Africa o Saudi Arabia o UAE o Kuwait Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Market Definitions 1.2.1. Workflow Segment 1.2.2. Technology Segment 1.2.3. Application Segment 1.2.4. End Use Segment 1.3. Information analysis 1.3.1. Market formulation & data visualization 1.4. Data validation & publishing 1.5. Information Procurement 1.5.1. Primary Research 1.6. Information or Data Analysis 1.7. Market Formulation & Validation 1.8. Market Model 1.9. Total Market: CAGR Calculation 1.10. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segmental Snapshot 2.3. Competitive Landscape Snapshot Chapter 3. Market Variables, Trends, and Scope 3.1. Market Lineage 3.1.1. Parent Market Analysis 3.1.2. Ancillary Market Analysis 3.2. Clinical Oncology NGS Market- Market Dynamics 3.2.1. Market Driver Analysis 3.2.2. Market Restraint Analysis 3.3. Market Analysis Tools 3.3.1. Porter’s Five Forces Analysis 3.3.2. PESTLE Analysis 3.3.3. COVID-19 Impact Analysis Chapter 4. Clinical Oncology NGS Market: Workflow Business Analysis 4.1. Workflow Segment Dashboard 4.2. Global Clinical Oncology NGS Market Workflow Movement Analysis, 2024 & 2033 4.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Workflow, 2021 to 2033 (USD Million) 4.4. NGS Pre-Sequencing 4.4.1. Global NGS Pre-Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million) 4.5. NGS Sequencing 4.5.1. Global NGS Sequencing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 4.6. NGS Data Analysis 4.6.1. Global NGS Data Analysis Market Estimates And Forecasts, 2021 - 2033 (USD Million) Chapter 5. Clinical Oncology NGS Market: Technology Business Analysis 5.1. Technology Segment Dashboard 5.2. Global Clinical Oncology NGS Market Technology Movement Analysis, 2024 & 2033 5.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million) 5.4. Whole Genome Sequencing 5.4.1. Global Whole Genome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million) 5.5. Whole Exome Sequencing 5.5.1. Global Whole Exome Sequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million) 5.6. Targeted Sequencing & Resequencing 5.6.1. Global Targeted Sequencing & Resequencing Market Estimates And Forecasts, 2021 - 2033 (USD Million) Chapter 6. Clinical Oncology NGS Market: Application Business Analysis 6.1. Application Segment Dashboard 6.2. Global Clinical Oncology NGS Market Application Movement Analysis, 2024 & 2033 6.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million) 6.4. Screening 6.4.1. Global Screening Market Estimates And Forecasts, 2021 - 2033 (USD Million) 6.5. Companion Diagnostics 6.5.1. Global Companion Diagnostics Market Estimates And Forecasts, 2021 - 2033 (USD Million) 6.5.2. Sporadic Cancer 6.5.2.1. Global Sporadic Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million) 6.5.3. Inherited Cancer 6.5.3.1. Global Inherited Cancer Market Estimates And Forecasts, 2021 - 2033 (USD Million) 6.6. Others 6.6.1. Global Others Market Estimates And Forecasts, 2021 - 2033 (USD Million) Chapter 7. Clinical Oncology NGS Market: End Use Business Analysis 7.1. End Use Segment Dashboard 7.2. Global Clinical Oncology NGS Market End Use Movement Analysis, 2024 & 2033 7.3. Global Clinical Oncology NGS Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million) 7.4. Clinics 7.4.1. Global Clinics Market Estimates And Forecasts, 2021 - 2033 (USD Million) 7.5. Hospitals 7.5.1. Global Hospitals Market Estimates And Forecasts, 2021 - 2033 (USD Million) 7.6. Laboratories 7.6.1. Global Laboratories Market Estimates And Forecasts, 2021 - 2033 (USD Million) Chapter 8. Clinical Oncology NGS Market: Regional Estimates & Trend Analysis by Workflow, Technology, Application, and End Use 8.1. Regional Market Share Analysis, 2024 & 2033 8.2. Regional Market Dashboard 8.3. Market Size, & Forecasts, Trend Analysis, 2021 to 2033: 8.4. North America 8.4.1. North America market estimates and forecasts 2021 to 2033 (USD Million) 8.4.2. U.S. 8.4.2.1. Key country dynamics 8.4.2.2. Competitive scenario 8.4.2.3. Regulatory framework 8.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million) 8.4.3. Canada 8.4.3.1. Key country dynamics 8.4.3.2. Competitive scenario 8.4.3.3. Regulatory framework 8.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million) 8.4.4. Mexico 8.4.4.1. Key country dynamics 8.4.4.2. Competitive scenario 8.4.4.3. Regulatory framework 8.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million) 8.5. Europe 8.5.1. Europe market estimates and forecasts 2021 to 2033 (USD Million) 8.5.2. UK 8.5.2.1. Key country dynamics 8.5.2.2. Competitive scenario 8.5.2.3. Regulatory framework 8.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million) 8.5.3. Germany 8.5.3.1. Key country dynamics 8.5.3.2. Competitive scenario 8.5.3.3. Regulatory framework 8.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million) 8.5.4. France 8.5.4.1. Key country dynamics 8.5.4.2. Competitive scenario 8.5.4.3. Regulatory framework 8.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million) 8.5.5. Italy 8.5.5.1. Key country dynamics 8.5.5.2. Competitive scenario 8.5.5.3. Regulatory framework 8.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million) 8.5.6. Spain 8.5.6.1. Key country dynamics 8.5.6.2. Competitive scenario 8.5.6.3. Regulatory framework 8.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million) 8.5.7. Denmark 8.5.7.1. Key country dynamics 8.5.7.2. Competitive scenario 8.5.7.3. Regulatory framework 8.5.7.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million) 8.5.8. Sweden 8.5.8.1. Key country dynamics 8.5.8.2. Competitive scenario 8.5.8.3. Regulatory framework 8.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million) 8.5.9. Norway 8.5.9.1. Key country dynamics 8.5.9.2. Competitive scenario 8.5.9.3. Regulatory framework 8.5.9.4. Norway market estimates and forecasts 2021 to 2033 (USD Million) 8.6. Asia Pacific 8.6.1. Asia Pacific market estimates and forecasts 2021 to 2033 (USD Million) 8.6.2. Japan 8.6.2.1. Key country dynamics 8.6.2.2. Competitive scenario 8.6.2.3. Regulatory framework 8.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million) 8.6.3. China 8.6.3.1. Key country dynamics 8.6.3.2. Competitive scenario 8.6.3.3. Regulatory framework 8.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million) 8.6.4. India 8.6.4.1. Key country dynamics 8.6.4.2. Competitive scenario 8.6.4.3. Regulatory framework 8.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million) 8.6.5. Australia 8.6.5.1. Key country dynamics 8.6.5.2. Competitive scenario 8.6.5.3. Regulatory framework 8.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million) 8.6.6. South Korea 8.6.6.1. Key country dynamics 8.6.6.2. Competitive scenario 8.6.6.3. Regulatory framework 8.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million) 8.6.7. Thailand 8.6.7.1. Key country dynamics 8.6.7.2. Competitive scenario 8.6.7.3. Regulatory framework 8.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million) 8.7. Latin America 8.7.1. Latin America market estimates and forecasts 2021 to 2033 (USD Million) 8.7.2. Brazil 8.7.2.1. Key country dynamics 8.7.2.2. Competitive scenario 8.7.2.3. Regulatory framework 8.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million) 8.7.3. Argentina 8.7.3.1. Key country dynamics 8.7.3.2. Competitive scenario 8.7.3.3. Regulatory framework 8.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million) 8.8. MEA 8.8.1. MEA market estimates and forecasts 2021 to 2033 (USD Million) 8.8.2. South Africa 8.8.2.1. Key country dynamics 8.8.2.2. Competitive scenario 8.8.2.3. Regulatory framework 8.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million) 8.8.3. Saudi Arabia 8.8.3.1. Key country dynamics 8.8.3.2. Competitive scenario 8.8.3.3. Regulatory framework 8.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million) 8.8.4. UAE 8.8.4.1. Key country dynamics 8.8.4.2. Competitive scenario 8.8.4.3. Regulatory framework 8.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million) 8.8.5. Kuwait 8.8.5.1. Key country dynamics 8.8.5.2. Competitive scenario 8.8.5.3. Regulatory framework 8.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million) Chapter 9. Competitive Landscape 9.1. Company/Competition Categorization 9.2. Strategy Mapping 9.3. Company Market Position Analysis, 2024 9.4. Company Profiles/Listing 9.4.1. Thermo Fisher Scientific Inc. 9.4.1.1. Company overview 9.4.1.2. Financial performance 9.4.1.3. Product benchmarking 9.4.1.4. Strategic initiatives 9.4.2. Illumina, Inc. 9.4.2.1. Company overview 9.4.2.2. Financial performance 9.4.2.3. Product benchmarking 9.4.2.4. Strategic initiatives 9.4.3. Myriad Genetics 9.4.3.1. Company overview 9.4.3.2. Financial performance 9.4.3.3. Product benchmarking 9.4.3.4. Strategic initiatives 9.4.4. F. Hoffmann-La Roche Ltd. 9.4.4.1. Company overview 9.4.4.2. Financial performance 9.4.4.3. Product benchmarking 9.4.4.4. Strategic initiatives 9.4.5. Agilent Technologies, Inc. 9.4.5.1. Company overview 9.4.5.2. Financial performance 9.4.5.3. Product benchmarking 9.4.5.4. Strategic initiatives 9.4.6. Perkin Elmer 9.4.6.1. Company overview 9.4.6.2. Financial performance 9.4.6.3. Product benchmarking 9.4.6.4. Strategic initiatives 9.4.7. Pacific Bioscience 9.4.7.1. Company overview 9.4.7.2. Financial performance 9.4.7.3. Product benchmarking 9.4.7.4. Strategic initiatives 9.4.8. Oxford Nanopore Technologies Ltd. 9.4.8.1. Company overview 9.4.8.2. Financial performance 9.4.8.3. Product benchmarking 9.4.8.4. Strategic initiatives 9.4.9. Eurofins Scientific S.E. 9.4.9.1. Company overview 9.4.9.2. Financial performance 9.4.9.3. Product benchmarking 9.4.9.4. Strategic initiatives 9.4.10. Qiagen N.V. 9.4.10.1. Company overview 9.4.10.2. Financial performance 9.4.10.3. Product benchmarking 9.4.10.4. Strategic initiatives
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（バイオ薬物）の最新刊レポート
Grand View Research社の 生物分野 での最新刊レポート
本レポートと同じKEY WORD（oncology）の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ（Grand View Research）は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
